Category Archives: People

U.S. Personal Care Products Industry Drives Nearly $500 Billion in Economic Output, Supports More Than 2.6 Million Jobs, New Report Finds

Beyond its essential role in the daily lives of consumers, the industry drives economic activity, fosters a diverse and highly skilled workforce, and champions innovation. Washington, D.C., May 18, 2026 (GLOBE NEWSWIRE) — The Personal Care Products Council (PCPC) today released its latest economic impact report, Beyond Beauty: Economic Impact of the U.S. Personal Care Products […]

Slay the Prom Night: How Gen Z is Shaking Up Graduation Hairstyles with Wigs

NORCROSS, Ga., May 18, 2026 (GLOBE NEWSWIRE) — As the May prom and graduation season swings into full gear, Gen Z is taking over social media feeds with a massive quest for “picture-perfect hair.” For graduates looking to transform their look without the long-term commitment or chemical damage of traditional salon services, high-quality human hair […]

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing Presented new analyses at AAN 2026 highlighting first-ever MRI data demonstrating evidence of reversible disease progression in the basal forebrain with neflamapimod treatment Presented new analyses at AD/PD™ 2026 demonstrating […]

BrainsWay Announces Minority-Stake Investment in Hopemark Health

Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Israel, May 18, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global […]

Zenflow Presents the BREEZE™ Pivotal Clinical Trial at the American Urological Association Annual Meeting

Data Supported the FDA Approval of the Zenflow Spring® Implant and Delivery System for BPH Additional presented data highlights patient satisfaction & long-term safety SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) — Zenflow, Inc. recently presented data from its BREEZE™ pivotal clinical trial demonstrating the efficacy and safety of the Zenflow Spring® Implant […]

Glass House Brands Announces the Filing of Prospectus Supplement for Previously Announced At-The-Market Distribution Program

LONG BEACH, Calif. and TORONTO, May 18, 2026 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company“) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) announced today that, further to its news release dated May 13, 2026, it has filed a prospectus supplement (the “Prospectus Supplement“) to its short form base shelf […]

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on track for mid-2026.  Independent, blinded biomechanical gait analyses of the CONNECT SCI study designed to differentiate genuine neural recovery from compensatory movement remain ongoing, with […]

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity  Patient satisfaction scores at Week 24 were 82.8%   Corabotase is currently being evaluated as an investigational treatment in aesthetic indications […]

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed Primary Response Evaluation (PRE) – – Updated durability data shows 85.7% (18/21) of patients who completed the Maintenance Treatment Phase (MTP) sustained CRs in the treated area for at least 12 months as of the […]

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab combination compared to pembrolizumab monotherapy Phase 3 head-to-head trial of the high-dose fianlimab combination versus Opdualag® (nivolumab and relatlimab-rmbw) is ongoing TARRYTOWN, N.Y., […]